Form 8-K

8-K — Ensysce Biosciences, Inc.

Accession: 0001493152-26-023810

Filed: 2026-05-15

Period: 2026-05-15

CIK: 0001716947

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001716947

2026-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 15, 2026 (May 15, 2026)

Ensysce

Biosciences, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-38306

82-2755287

(State

or other jurisdiction

incorporation or organization)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

7946

Ivanhoe Avenue, Suite 201

Jolla, California

92037

(Address

of principal executive offices)

(Zip

Code)

(858)

263-4196

Registrant’s

telephone number, including area code

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

ENSC

The

Nasdaq Stock Market LLC

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02. Results of Operations and Financial Condition.

May 15, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for

the fiscal quarter ended March 31, 2026. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

The

information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended, nor will they be deemed to be incorporated by reference in any filing

under the Securities Act of 1933, as amended, except as will be expressly set forth by specific reference in such a filing.

Forward-Looking

Statements

This

report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. These statements may be made directly in this report. Some of the forward-looking

statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,”

“expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,”

“targets,” “projects,” “should,” “could,” “would,” “may,” “will,”

“forecast” and other similar expressions are intended to identify forward-looking statements. All forward-looking statements

are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of

the date of this report, and may include, without limitation, changes in general economic and political conditions, all of which are

accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this report constitute

the Company’s judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking

statements and projections contained in this report are subject to a number of factors, risks and uncertainties, some of which are not

currently known to the Company, that may cause the Company’s actual results, performance or financial condition to be materially

different from the expectations of future results, performance of financial condition. Although such forward-looking statements have

been made in good faith and are based on assumptions that the Company believes to be reasonable, there is no assurance that the expected

results will be achieved. The Company’s actual results may differ materially from the results discussed in forward-looking statements.

Additional information on factors that may cause actual results and the Company’s performance to differ materially is included

in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Copies of such filings with the SEC

are available publicly on the SEC’s website at www.sec.gov or may be obtained by contacting the Company. Readers are cautioned

not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements

are made only as of the date hereof, and the Company does not undertake any obligations to update or revise the forward-looking statements,

whether as a result of new information, future events or otherwise, except as required by law.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

Number

Description

99.1

Press Release, dated May 15, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

Dated:

May 15, 2026

Ensysce

Biosciences, Inc.

By:

/s/

Lynn Kirkpatrick

Name:

Dr.

Lynn Kirkpatrick

Title:

President

and Chief Executive Officer

(Principal

Executive Officer)

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Ensysce

Biosciences Reports First Quarter 2026 Financial Results

IRB Approval Secured for PF614-MPAR-102 Part 3 ~

Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~

~Company Launches Formal Review of Strategic Alternatives ~

SAN

DIEGO, CA / May 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage

pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose

risk, today reported financial and operational results for the first quarter ended March 31, 2026.

“The

first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, underscoring the strength of our strategy

and the discipline of our execution,” said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. We achieved 50% of

the interim enrollment target in our pivotal PF614-301 Phase 3 trial, published the first peer-reviewed clinical data validating our

MPAR® overdose-protection technology, and expanded our patent estate across both our opioid and ADHD programs. Together

these milestones reinforce what we believe is the next evolution of opioid safety.”

Dr.

Kirkpatrick continued, “Following quarter-end, we closed a second financing tranche under an existing facility and secured IRB

approval to initiate Part 3 of PF614-MPAR-102, the final stage of that study. Advancing this program strengthens the clinical evidence

supporting a product we believe can fundamentally reshape how overdose risk is managed. In parallel, our Board has initiated a formal

review of strategic alternatives, including potential partnerships and licensing opportunities, to accelerate the development of our

TAAP™ and MPAR® platforms and unlock additional shareholder value.”

TAAPTM

(Opioid Abuse Deterrent Program) Update

PF614

is the Company’s lead product candidate and represents what we believe could be a next-generation extended-release oxycodone with

built-in abuse protection. Developed using our proprietary Trypsin-Activated Abuse Protection (TAAP™) technology, PF614 remains

inactive until it is swallowed and exposed to trypsin in the small intestine, where it “switches on” to release oxycodone

in a controlled manner.

This

targeted activation is designed to deliver effective pain relief while significantly reducing the potential for manipulation or

non-oral abuse. By making the active drug inaccessible until it reaches the digestive tract, TAAP™ aims to provide a safer opioid

option for patients with severe pain who require opioid-strength therapy. The Company believes this approach has the potential to meaningfully

differentiate PF614 within the multi-billion-dollar pain management market and address longstanding concerns around tampering and misuse.

January, Ensysce announced that it had enrolled 50% of the subjects targeted for interim review in its pivotal PF614-301 Phase 3 clinical

trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating PF614 for the treatment of moderate to severe pain

following abdominoplasty. Enrollment, which began in late December 2025, progressed across two U.S. clinical sites; CenExel JBR

(Salt Lake City, Utah) and CenExel Atlanta (Decatur, Georgia), under principal investigators Dr. Todd Bertoch and Dr. Jessica McCoun,

recognized experts in anesthesiology and pain management. The study is designed to demonstrate PF614’s ability to deliver consistent,

clinically meaningful post-surgical pain relief using twice-daily dosing while leveraging its built-in abuse protection chemistry. Achieving

the interim enrollment milestone in the early stages of the program brings Ensysce meaningfully closer to delivering interim data and

advancing what the Company believes could be a new standard in acute pain management.

MPAR®

(Opioid Abuse Deterrent and Overdose Protection Program) Update

PF614-MPAR

is the Company’s next-generation combination product that integrates both the TAAPTM and MPAR® (Multi-Pill

Abuse Resistance) technology to deliver effective opioid analgesia with the added benefit of built-in oral overdose protection. By pairing

the PF614 prodrug with a trypsin inhibitor, PF614-MPAR is designed to “switch off” opioid release when supratherapeutic doses

are taken, offering a differentiated safety profile aimed at reducing overdose risk while maintaining therapeutic efficacy for patients

with severe pain.

Initial

clinical data from the PF614-MPAR-101 study demonstrated that the MPAR® mechanism performed as intended at a 25 mg dose,

providing the desired overdose protection. These results supported the FDA’s decision to grant Breakthrough Therapy designation

in January 2024, a key regulatory milestone that underscores the potential for PF614-MPAR to address a significant unmet need in opioid

safety.

March, Ensysce announced the publication of the first peer-reviewed clinical manuscript describing its MPAR® overdose

protection technology in the January/February 2026 issue of the Journal of Opioid Management. The paper, “Formulation and a Phase

1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection,” reported that PF614-MPAR achieved appropriate

opioid plasma levels under normal dosing conditions while preventing large increases in exposure at supratherapeutic doses— reinforcing

the potential for a fundamentally new safety paradigm in opioid analgesia.

Following

quarter end, in April 2026, Ensysce received Institutional Review Board (IRB) approval to initiate Part 3 of the PF614-MPAR-102

study, the final stage in evaluating the MPAR® overdose-protection technology. Part 3 is designed to further characterize

PF614-MPAR‘s protective effect across multiple dosing scenarios, building on the previously published data demonstrating that the

product delivers therapeutic plasma levels under normal use while significantly limiting additional opioid exposure when higher-than-prescribed

doses are taken. The study continues with support from the National Institute on Drug Abuse (NIDA), reflecting ongoing external validation

of the program’s potential impact.

ADHD

Program Update

Ensysce

is leveraging its TAAP™ and MPAR® platforms beyond pain management to develop what could become the first abuse-deterrent,

overdose-protected stimulant therapies for attention-deficit/hyperactivity disorder (ADHD). The Company’s ADHD pipeline includes

PF8026, a novel immediate-release amphetamine prodrug, and PF8001, an extended-release candidate. In January 2026, Ensysce received a

Notice of Allowance from the European Patent Office for a patent covering PF8026, with both composition-of-matter and method-of-use claims.

This strengthens the Company’s intellectual property position and supports long-term value creation as it allows advancement of

safer stimulant options for a large and growing market. The need for innovation in ADHD therapeutics is significant. In 2023, approximately

3.9 million people aged 12 or older misused prescription stimulants, highlighting the limitations of current treatments and the urgency

for products engineered to resist common routes of abuse and incorporate overdose protection mechanisms. By applying TAAP™ and

MPAR® to stimulant medications, Ensysce has the ability to address this unmet need and expand its platform into another

major therapeutic category with substantial commercial potential.

Opioid

Use Disorder (OUD) Program Update

Beyond

its pain management portfolio, Ensysce is advancing treatments for opioid use disorder (OUD) aimed at reducing cravings, lower relapse

risk, and improving long-term patient outcomes while maintaining patient safety and quality of life. The Company has selected PF9001

as its lead OUD candidate and is evaluating it as a potential next-generation alternative to methadone, with the added advantage of built-in

overdose protection, reduced cardiovascular risk and convenient oral delivery profile. The PF9001 program has been supported by a multi-year

HEAL (Helping to End Addiction Long-Term) grant and in collaboration with NIDA. This program support provides both scientific validation

and non-dilutive funding, reinforcing the potential of PF9001 to address critical gaps in current OUD treatment options and expand the

application of Ensysce’s TAAP™ and MPAR® technologies into another major public health challenge.

2026 Financial Results

Cash

- Cash and cash equivalents were $0.7 million as of March 31, 2026, compared to $4.3 million as of December 31, 2025. Subsequent

to March 31, 2026, on April 7, 2026, the Company closed a second tranche of $2.0 million in convertible preferred stock financing under

its previously announced November 2025 commitment for up to $20 million over 24 months.

Federal

Grants - Funding under federal grants totaled $1.0 million for the first quarter of 2026 compared to $1.3 million in the comparable

year ago quarter. This $0.3 million decrease is primarily due to the timing of research activities eligible for funding under the MPAR

grant.

Research

& Development Expenses - R&D expenses were $3.3 million for the first quarter of 2026 compared to $1.9 million for the same

period in 2025, representing an increase of $1.4 million. The increase was primarily the result of external research and development

costs related to Phase 3 clinical trial activity for PF614.

General

& Administrative Expenses - G&A expenses were $1.2 million in the first quarter of 2026 and $1.4 million for the first quarter

of 2025, representing a decrease of $0.2 million.

Net

Income (Loss) - Net loss attributable to common stockholders for the first quarter of 2026 was $3.6 million compared to a net loss

of $1.9 million for the first quarter of 2025. As a clinical stage biotech company, our continued research and development efforts toward

regulatory approvals for our product candidates are expected to result in losses for the foreseeable future.

About

Ensysce Biosciences

Ensysce

Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel

opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance

(MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of

both drug abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe

pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.

Definitions

TAAP™:

trypsin-activated abuse protection - designed to protect against prescription drug abuse.

MPAR®:

multi-pill abuse resistance - designed to protect against abuse and accidental overdose.

Forward-Looking

Statements

contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the

safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting

the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,”

“expect,” “plan,” “possible,” “believe” and other similar expressions are intended to

identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that

the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays

in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking

statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are

inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially

from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among

others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability

of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns

related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; continuation

of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect

of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under their license, collaboration

and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described

in Ensysce’s most recent annual report on Form 10-K and current reports on Form 8-K, available free of charge at the SEC’s

website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation

to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except

as required under applicable law.

Ensysce

Biosciences Company Contact:

Lynn

Kirkpatrick, Ph.D.

Chief

Executive Officer

(858)

263-4196

Ensysce

Biosciences Investor Relations Contact:

Shannon

Devine

North America

Main:

203-741-8811

ENSC@mzgroup.us

Ensysce

Biosciences, Inc.

Condensed

Consolidated Statements of Operations

(Unaudited)

Three Months Ended March 31,

2026

2025

Federal grants

$ 960,999

$ 1,319,772

Operating expenses:

Research and development

3,346,881

1,885,528

General and administrative

1,176,348

1,401,756

Total operating expenses

4,523,229

3,287,284

Loss from operations

(3,562,230 )

(1,967,512 )

Total other income (expense), net

5,815

21,939

Net loss

$ (3,556,415 )

$ (1,945,573 )

Net loss per share, basic and diluted

$ (0.52 )

$ (1.39 )

Ensysce

Biosciences, Inc.

Condensed

Consolidated Statements of Cash Flows

(Unaudited)

Three Months Ended March 31,

2026

2025

Net cash used in operating activities

$ (3,500,925 )

$ (1,707,412 )

Net cash (used in) provided by financing activities

(63,947 )

1,257,826

Change in cash and cash equivalents

(3,564,872 )

(449,586 )

Cash and cash equivalents at beginning of period

4,310,354

3,502,077

Cash and cash equivalents at end of period

$ 745,482

$ 3,052,491

Ensysce

Biosciences, Inc.

Condensed

Consolidated Balance Sheets

(Unaudited)

March 31,

December 31,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$ 745,482

$ 4,310,354

Prepaid expenses and other current assets

1,263,058

2,934,664

Total current assets

2,008,540

7,245,018

Other assets

159,263

207,461

Total assets

$ 2,167,803

$ 7,452,479

Liabilities and stockholders’ equity (deficit)

Current liabilities:

Accounts payable

$ 1,610,186

$ 3,267,610

Accrued expenses and other liabilities

980,780

993,411

Notes payable and accrued interest

245,849

306,708

Total current liabilities

2,836,815

4,567,729

Long-term liabilities

—

Total liabilities

2,836,815

4,567,729

Stockholders’ equity (deficit)

(669,012 )

2,884,750

Total liabilities and stockholders’ equity

$ 2,167,803

$ 7,452,479

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 15, 2026

Entity File Number

001-38306

Entity Registrant Name

Ensysce

Biosciences, Inc.

Entity Central Index Key

0001716947

Entity Tax Identification Number

82-2755287

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7946

Ivanhoe Avenue

Entity Address, Address Line Two

Suite 201

Entity Address, City or Town

Jolla

Entity Address, State or Province

Entity Address, Postal Zip Code

92037

City Area Code

(858)

Local Phone Number

263-4196

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

ENSC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration